Search clinical trials for: BG00012 placebo

Total 53978 results

Biogen

Completed

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Bulgaria, Belgium, Poland, Lithuania, Kuwait, Turkey
Biogen

Completed

Study of Utilization Patterns of Dimethyl Fumarate in Germany

Multiple Sclerosis

Germany
Biogen

Withdrawn

Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate (TECNERGY)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Multiple Sclerosis, Relapsing-Remitting

United States, Spain, Canada, Australia, Germany, Italy, United Kingdom, Belgium, Netherlands, France, Israel
Biogen

Terminated

Natalizumab Subcutaneous Immunogenicity and Safety Study (SIMPLIFY)

Relapsing Multiple Sclerosis

Belgium
Biogen

Terminated

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring (INFORM)

Crohn's Disease

United States, Puerto Rico
Biogen

Completed

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (STRIVE)

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS (TYNERGY)

Fatigue | Relapsing-Remitting Multiple Sclerosis

Sweden, Norway, Austria, Denmark
Biogen

Completed

Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab (PROTYS)

Multiple Sclerosis

Switzerland
Biogen

Completed

Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri

Multiple Sclerosis
Siesta Medical, Inc.

Terminated

FAST as a Treatment for Obstructive Sleep Apnea (FAST)

Obstructive Sleep Apnea

United States
Biogen

Completed

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (TYPIFI)

Relapsing Remitting Multiple Sclerosis

Portugal
Biogen

Terminated

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies (ESCALATE)

Relapsing Multiple Sclerosis

United States
Biogen

Completed

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function (TRUST)

Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Japan
Biogen
Elan Pharmaceuticals; United BioSource, LLC

Completed

JC-Virus (JCV) Antibody Program (STRATIFY-1)

Multiple Sclerosis

United States
Biogen

Active, not recruiting

A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Multiple Sclerosis

China
Biogen

Completed

PK and PD Study of Natalizumab in Pediatric Subjects With RRMS

Relapsing-Remitting Multiple Sclerosis

Italy
Biogen

Completed

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis

Russian Federation
Yale University
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

Calcitonin for Treating X-linked Hypophosphatemia

Hypophosphatemic Rickets, X Linked Dominant

United States
Biogen

Completed

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Multiple Sclerosis | Exposure During Pregnancy

Spain, Italy, Australia, Poland, United Kingdom, United States, Canada, France, Germany, Ireland
Biogen

Completed

Tecfidera and the Gut Microbiota (TECONGUT)

Multiple Sclerosis, Relapsing-Remitting

Norway
Biogen
Elan Pharmaceuticals

Completed

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals

Completed

Natalizumab High Titer Immunogenicity and Safety

Multiple Sclerosis

United States
Biogen

Completed

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis (EXPLORE)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS (RESPOND)

Relapsing Forms of Multiple Sclerosis

United States
Biogen

Terminated

Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting | Relapsing-Remitting Multiple Sclerosis

Canada
Biogen
Elan Pharmaceuticals

Completed

A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State

Multiple Sclerosis

United States
Biogen

Completed

Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases

Colorectal Carcinoma | Metastases

United States
Biogen

Completed

PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily

Healthy

United States
Biogen

Completed

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

Progressive Multifocal Leukoencephalopathy

United States
Sheba Medical Center

Withdrawn

Pilot Study of AdvanStep in Improving Balance in at Risk Elderly (AdvanStep)

Impaired Balance in Elderly

Israel
Biogen

Terminated

Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.

Multiple Sclerosis

United States
Biogen

Not yet recruiting

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Multiple Sclerosis
Biogen

Completed

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera (MITIGATE)

Multiple Sclerosis

United States
Biogen

Completed

Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis (ASSURE)

Relapsing-Remitting Multiple Sclerosis

United Kingdom, Ireland
Biogen

Terminated

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants (REVEAL)

Relapsing-Remitting Multiple Sclerosis

United States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
Biogen

Completed

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States
Ege University

Completed

Care to Caregiver: The Effect of Reflexology on Sleep and Anxiety of Cancer Caregiver

Sleep | Anxiety

Turkey
Biogen

Active, not recruiting

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CONNECT)

Relapsing-Remitting Multiple Sclerosis

Italy, Belgium, United States, Hungary, Sweden, United Kingdom, Israel, France, Czechia, Poland, Serbia, Denmark, Spain, Turkey, Bulgaria, Germany, Canada, Kuwait
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder (DEPIL-2)

Bipolar Depression

France
Washington University School of Medicine

Completed

Alirocumab and Reverse Cholesterol Transport

Atherosclerosis | Coronary Heart Disease

United States
Orphan Australia

Completed

VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

Crohn's Disease

Australia
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
Chinese University of Hong Kong

Recruiting

RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19

COVID-19

Hong Kong
National University of Malaysia
Malaysia Palm Oil Board

Unknown

Supplementation of Oil Palm Phenolics to Healthy Participants (SPIRAL)

Cardiovascular Diseases | Hypercholesterolemia | Hyperlipidemias

Malaysia
University of South Carolina
U.S. Army Medical Research and Development Command

Completed

Dietary Seaweed and Early Breast Cancer: A Randomized Trial

Seaweed Associated Changes in Healthy Subjects

United States
Gladwin, Mark, MD
National Institutes of Health (NIH); National Institute on Aging (NIA)

Completed

Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age (Nitrite)

Sedentary Lifestyle | Frailty | Aging

United States
Mersin University

Completed

The Effect of Post-Cesarean Section Acupressure on the Severity of Pain and First Mobilization Distance (Acupress)

Pain | Mobilization

Turkey
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Active, not recruiting

Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)

Critical Limb Ischemia

Poland

3

Subscribe